Sterile normal saline (0.9%)

DRUG3 trials

Sponsors

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd

Conditions

COVID-19Covid19Malaria (Plasmodium Falciparum)

Phase 1

Clinical Study of Meplazumab to Treat With Malaria

WithdrawnNCT04327310

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co LtdMalaria (Plasmodium Falciparum)

Start: 2023-03-31End: 2024-03-31Updated: 2023-09-21

Phase 2

Study to Assess the Effect of Meplazumab on COVID-19

CompletedNCT04586153

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co LtdCOVID-19

Start: 2021-02-15End: 2022-12-18Updated: 2023-09-15

the Safety and Efficacy of Meplazumab in Patients With COVID-19

CompletedNCT05113784

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co LtdCovid19

Start: 2022-01-21End: 2022-10-08Updated: 2023-09-15

Related Papers

Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial

Signal Transduction and Targeted Therapy2025-04-132 citations

Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial

Signal Transduction and Targeted Therapy2023-01-3016 citations